User profiles for Natalia T Freund
 | Natalia Tarnovitski FreundSenior lecturer (Assistant Professor) Verified email at tauex.tau.ac.il Cited by 3011 |
Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity
D Hagin, T Freund, M Navon, T Halperin, D Adir… - Journal of Allergy and …, 2021 - Elsevier
Background In mid-December 2020, Israel started a nationwide mass vaccination campaign
against coronavirus disease 2019 (COVID-19). In the first few weeks, medical personnel, …
against coronavirus disease 2019 (COVID-19). In the first few weeks, medical personnel, …
[PDF][PDF] HIV vaccine design to target germline precursors of glycan-dependent broadly neutralizing antibodies
Broadly neutralizing antibodies (bnAbs) against the N332 supersite of the HIV envelope (Env)
trimer are the most common bnAbs induced during infection, making them promising …
trimer are the most common bnAbs induced during infection, making them promising …
[PDF][PDF] Sequential immunization elicits broadly neutralizing anti-HIV-1 antibodies in Ig knockin mice
A vaccine that elicits broadly neutralizing antibodies (bNAbs) against HIV-1 is likely to be
protective, but this has not been achieved. To explore immunization regimens that might elicit …
protective, but this has not been achieved. To explore immunization regimens that might elicit …
[PDF][PDF] Immunization for HIV-1 broadly neutralizing antibodies in human Ig knockin mice
A subset of individuals infected with HIV-1 develops broadly neutralizing antibodies (bNAbs)
that can prevent infection, but it has not yet been possible to elicit these antibodies by …
that can prevent infection, but it has not yet been possible to elicit these antibodies by …
Lower serologic response to COVID-19 mRNA vaccine in patients with inflammatory bowel diseases treated with anti-TNFα
Background & Aim Patients with inflammatory bowel diseases (IBD), specifically those
treated with anti–tumor necrosis factor (TNF)α biologics, are at high risk for vaccine-preventable …
treated with anti–tumor necrosis factor (TNF)α biologics, are at high risk for vaccine-preventable …
Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice
VRC01-class broadly neutralizing HIV-1 antibodies protect animals from experimental infection
and could contribute to an effective vaccine response. Their predicted germline forms (gl) …
and could contribute to an effective vaccine response. Their predicted germline forms (gl) …
Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller
Some HIV-1–infected patients develop broad and potent HIV-1 neutralizing antibodies (bNAbs)
that when passively transferred to mice or macaques can treat or prevent infection. …
that when passively transferred to mice or macaques can treat or prevent infection. …
[HTML][HTML] Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo
…, TLGM van den Kerkhof, NT Freund… - Journal of Experimental …, 2017 - rupress.org
Induction of broadly neutralizing antibodies (bNAbs) by HIV-1 envelope glycoprotein
immunogens would be a major advance toward an effective vaccine. A critical step in this process …
immunogens would be a major advance toward an effective vaccine. A critical step in this process …
Structural characterization of a highly-potent V3-glycan broadly neutralizing antibody bound to natively-glycosylated HIV-1 envelope
Broadly neutralizing antibodies (bNAbs) isolated from HIV-1-infected individuals inform HIV-1
vaccine design efforts. Developing bNAbs with increased efficacy requires understanding …
vaccine design efforts. Developing bNAbs with increased efficacy requires understanding …
Human antibodies targeting a Mycobacterium transporter protein mediate protection against tuberculosis
Mycobacterium tuberculosis (Mtb) exposure drives antibody responses, but whether patients
with active tuberculosis elicit protective antibodies, and against which antigens, is still …
with active tuberculosis elicit protective antibodies, and against which antigens, is still …
